盘后桑加莫治疗公司股票大涨：发生了什么？-动脉网

Sangamo Therapeutics Stock Surges After The Bell: What's Going On?

benzinga 等信源发布 2025-04-03 16:46



可切换为仅中文







Sangamo Therapeutics Inc

桑加莫治疗公司

SGMO

shares are surging in Thursday’s after-hours session after the company announced a new agreement with

周四盘后交易中，该公司宣布与新协议达成后，股价飙升。

pharmaceutical giant

制药巨头

Eli Lilly And Co

礼来公司

LLY

。

What Happened:

发生了什么：

Sangamo Therapeutics entered into a license agreement with Eli Lilly, granting the company a worldwide exclusive license to leverage the company’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.

Sangamo Therapeutics与Eli Lilly签订了许可协议，授予该公司在全球范围内独家使用其新型专有的神经向性腺相关病毒（AAV）衣壳STAC-BBB的权利。

Sangamo noted that STAC-BBB has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates.

Sangamo 指出，STAC-BBB 已在非人灵长类动物中显示出强大的血脑屏障穿透能力和神经元转导能力。

The genomic medicine company said the license allows Eli Lilly to utilize the STAC-BBB capsid for one initial target. Eli Lilly has the right to add up to four additional targets, but will be required to pay additional license fees.

这家基因组医学公司表示，该许可允许礼来公司针对一个初始目标使用STAC-BBB衣壳。礼来公司有权增加多达四个额外目标，但需支付额外的许可费用。

Sangamo will receive an upfront payment of $18 million and is eligible to earn up to $1.4 billion in additional license fees and milestone payments.

Sangamo将获得1800万美元的预付款，并有资格获得高达14亿美元的额外许可费和里程碑付款。

“We believe STAC-BBB, our industry-leading intravenously delivered AAV capsid, has the potential to play an important role in the treatment landscape by addressing longstanding challenges associated with delivering therapies to the central nervous system,” said

“我们相信，STAC-BBB作为一种行业领先的静脉注射AAV衣壳，有潜力通过解决长期以来与中枢神经系统治疗递送相关的挑战，在治疗领域发挥重要作用，”表示。

Sandy Macrae

桑迪·麦克雷

, CEO of Sangamo.

，Sangamo公司首席执行官。

“We are pleased to be sharing STAC-BBB with Lilly to advance potential treatments for neurological diseases with significant unmet medical needs. This marks the third agreement with a pharmaceutical company since we announced the discovery of STAC-BBB in March 2024 and demonstrates the continued industry interest in our capsid delivery technology.”.

“我们很高兴与礼来公司分享STAC-BBB，以推进对具有重大未满足医疗需求的神经系统疾病的潜在治疗。这是自我们在2024年3月宣布发现STAC-BBB以来与制药公司的第三份协议，表明业界对我们衣壳递送技术的持续关注。”

Sangamo will be responsible for completing a technology transfer related to the STAC-BBB capsid. Lilly will be responsible for all research, preclinical and clinical development, regulatory interactions, manufacturing and global commercialization of any resulting gene therapy products.

Sangamo将负责完成与STAC-BBB衣壳相关的技术转让。Lilly将负责所有由此产生的基因治疗产品的研究、临床前和临床开发、监管互动、生产和全球商业化。

SGMO Price Action:

SGMO价格走势：

Sangamo shares

Sangamo股票

were up 26.13% after hours, trading at 78 cents at the time of publication Thursday, according to

在周四发布时，盘后交易价格上涨了26.13％，交易价格为78美分。

Benzinga Pro

。

Photo: Courtesy of Sangamo Therapeutics.

照片来源：Sangamo Therapeutics 提供。

SGMO